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Guide to Clinical Trials
B. Spilker, New York: Raven Press, 1991, 1156 pp. $162.50.
This enormous single author book is written to explain the
practical details of clinical trials. The 133 chapters cover the
details of trial design, writing a protocol, aspects of statistics,
the interpretation of response and efficacy data, how to
publish results and the regulatory and managerial aspects of
trials.
Within the chapters Dr Spilker tries to explain the basic
principles of what is to be discussed or investigated and to
give a flow diagram or table of how to go about getting the
data, or analysing it. He writes clearly but the text is often
rather tediously generalised so that, for example, in the dis-
cussion of trial size there is a brief resume of a and P errors,
but little insight into how the trial size relates to the clinical
importance of the question (whether, for example, the size of
any difference needs to be quantified precisely). There is little
insight into the importance of statistical methodology
generally. Some of the chapters appear strangely out of
place. There are for example 33 pages on preparing an article
for publication and assessing the quality of a paper you have
read. Much of this consists ofpages of tables. There is a long
series of chapters on the goals and strategies of marketing
and drug development which may be of interest to phar-
maceutical companies but seem somewhat beside the point
for clinicians.
Almost everything and anything to do with trials is
touched on in this book. That is both a strength and a
weakness. I suppose that the professional group who would
find it most valuable are the clinical co-ordinators of research
in pharmaceutical companies, especially in the USA (there
are concessions to regulatory authorities elsewhere in the
world). I don't really recommend it for oncologists involved
in trials since it is not detailed enough in certain key areas
and contains much information and advice which is redun-
dant for cancer trials.
R.L. Souhami
Introducing New Treatment for Cancer. Practical, Ethical and
Legal Problems
Edited by C.J. Williams, Chichester: John Wiley & Sons,
1992, 492 pp. £24.95.
This book is long overdue. There can be few investigators
involved in testing new cancer treatments who have not been
concerned by at least some of the many difficult problems
discussed. The international list of contributors include
lawyers, ethicists, social scientists, statisticians, phar-
macologists, editors of medical journals, physicians working
for pharmaceutical companies, radiotherapists, medical
oncologists and specialists in community care. The book is
divided into five sections. Section 1 deals with legal (UK and
international) and ethical aspects of clinical trials and with
patients' attitudes to such therapy. In addition there are
chapters on informed consent, research ethics committees
and a summary of the Royal College of Physicians report on
Research Involving Patients. Informed consent comes up
again in Section 2 which discusses specific issues in trials of
new cancer treatments including the question of whether
patients in trials do better than those treated routinely. There
are chapters on phase I studies, 'the uncertainty principle'
design for randomised trials, randomisation before consent
(Zelen) designs, interim analysis and experiments on the
dying. Section 3 considers the pharmaceutical industry's role
and economic issues. Section 4 discusses trials for pre-
malignant lesions and chemoprevention trials and the final
section concerns itself with reporting policies, overviews and
the adoption of new treatments into clinical practice. Prior to
each section the editor, Chris Williams, gives a very helpful
outline of the areas to be discussed. Here he does not merely
summarise the views expressed, but focuses the more impor-
tant elements as well as voicing personal views which may
not always coincide with those of the chapter authors. This
serves as a most refreshing highlight to the controversial
aspects, particularly those surrounding informed consent.
The story of the reaction of the late Dr Franz Ingelfinger
(editor of the New England Journal of Medicine) on learning
that he had oesophageal cancer illustrates beautifully the
important difference between what the cancer patient may
want in terms of information and what others believe he
should have. For this experienced physician his illness was
much easier to cope with when he found a more traditionally
paternalistic doctor who was prepared to make the treatment
decisions for him. In section 2, various specific problem areas
are covered. For example, in his introduction the editor
touches on the difficulty of testing new drugs in chemosen-
sitive tumours. If one uses the new drug first and it turns out
to be ineffective then there will be a delay in introducing
standard effective treatment and drug resistance may be
induced. On the other hand if one waits till the patient no
longer responds to standard treatment, then multiple drug
resistance may have developed and the true efficacy of the
new drug will not emerge. Williams suggests that trials
should randomise patients to the new drug followed by the
phase II drug on progression. This is a very unwieldy solu-
tion which would not provide any general truths about the
safety or not of using new drugs in previously untreated
patients and could not possibly be repeated for each drug
because of the large number of patients that would be
required. Unfortunately this problem is not developed further
in the book and is the principal omission in what is otherwise
a comprehensive examination of the dilemmas facing new
cancer drug investigators. Section 3 deals with the phar-
maceutical industry and economic considerations. It is the
weakest section. The chapter on economic evaluation of
cancer treatments is, in places, banal (e.g. Figure 2), in others
confusing ('The efficacy and effectiveness of chemotherapy in
solid tumours are ambiguous'), and in others still poorly
described (Figure 4). A discussion of the implications for
governments struggling to finance ever more costly health
care is lacking. At the end of each chapter there is a useful
brief biography ofthe authors and a reference list. The text is
well laid out and a reasonably comprehensive index has been
compiled. Dr Williams is to be congratulated on assembling
an intriguing list of authors who have put together a fas-
cinating book which, although not offering any particularly
novel solutions to the many problems involved in the int-
roduction of new cancer treatments, certainly has them dis-
cussed clearly and, for the first time, grouped in a single text.
M.H. Cullen
Breast Cytology in Clinical Practice
S. Catania & S. Ciatto, London: Martin Dunitz, 1991,
136 pp. £39.95.
Fine needle aspiration cytology is used increasingly in the
investigation and management of breast disease, and to be
successful, requires the combined skills of clinician,
radiologist and cytopathologist.
First published in Italy, in 1989, this book is particularly
directed to the practical problems of obtaining material from
breast lesions and providing adequate preparations for cyto-
pathological evaluation. There is useful discussion of the role
of the cytopathologist, with guidance on the interpretation
and practical application of results. Although mainly con-
cerned with FNA, the indications for examination of cyst
fluids and nipple discharge are also presented in the light of
considerable clinical experience.
In addition the 14 sections (120 pages) with references and
illustrations cover a number of other aspects, including
historical background, physical examination of the breast,
use of ultrasound and stereotaxis, and the measurement of
oestrogen-receptor content. Possible hazards of needle aspira-1208 BOOK REVIEWS
tion, and the occasional complications of breast aspiration in
particular, are discussed in detail.
As might be expected in a multi-author book there is some
variation in the quality, and some overlap in content of the
contributions. It is a pity that the layout of text and photo-
graphs in a major section, on instruments and techniques, is
disjointed, making reading uncomfortable. Many of the
detailed photographs, although not difficult to understand,
have no legends, and are separated from the relevant text.
I agree with Professor David L. Page in his foreword that
'the value of this slim, multi-author volume lies in the wealth
of clinical experience presented.'
Anyone faced with having to start using fine needle aspira-
tion of the breast in clinical practice, and more especially
with being the aspirator, should find this book helpful.
J. Lamb
Xenobiotics and Cancer. Implications for Chemical Car-
cinogenesis and Cancer Chemotherapy
Edited by L. Ernster, H. Esumi, Y. Fujii, H.V. Gelboin, R.
Kato & T. Sugimura, Tokyo/London: Japan Scientific Press/
Taylor & Francis Ltd, 1991, 368 pp. £85.00.
This volume describes the Proceedings of the 21st Interna-
tional Symposium of the Princess Takamatsu Cancer
Research Fund, which was held in Tokyo, 1990. This Sym-
posium was largely concerned with the metabolic activation
of chemical carcinogens and anti-cancer drugs, with the
defense mechanisms against their action, and with the
biomonitoring methods available for detecting exposure to
those compounds. Publications of conference proceedings are
often rather dreary volumes, consisting of highly specialised
chapters, bearing little relation to each other. This book in
contrast provides an excellent survey of current biochemical
thinking on chemical, molecular biological and phar-
macological aspects of carcinogenesis. The authors are world
experts in their respective fields and the topics for the
chapters have in general been logically thought out. The
result is an impressive, almost text-book like, discussion of
chemical carcinogenesis, which will be of value to all post-
graduates and research workers in this field.
The book is divided into six sections and carries 30
chapters, each by different authors. The first section comp-
rises reports of two keynote lectures, the first covering
cytochrome P450 distribution and function (Gelboin et al.)
and the second covering the importance of the balance
between active oxygen species and antioxidants in the car-
cinogenesis process (Ernster). The cytochrome P450 multi-
enzyme family is the primary factor responsible for the
activation and detoxification of xenobiotics and the utility of
monoclonal antibodies and cDNA expression for the mapp-
ing of P450 distribution and function was concisely sum-
marised by Gelboin. The concept was presented by Ernster
that chemical carcinogenesis and its prevention may have as
a common denominator the metabolic activation of a
xenobiotic, which may result in the production of active
oxygen (which is involved in the initiation, promotion and
progression stages of carcinogenesis) or of antioxidant
mechanisms which can scavage these radicals and prevent
their harmful effects.
Metabolic activation of xenobiotics was further considered
in Section 2. Much evidence was (rightly) placed on the role
of cytochrome P450s, the topics discussed being the influence
of the anticarcinogen dehydroepiandrosterone on P450, the
pharmacogenetics and polymorphism of P450's, and the
aromatase cytochrome P450 complex. The possible contribu-
tion of (non-cytochrome P450 dependent) oxygen radicals to
bioactivation of carcinogens is a further important
parameter, which was discussed using benzo(a)pyrene as an
example. Other bioactivation processes that were reviewed
were those involving glutathione conjugate formation (e.g.
1,2-dihaloalkanes), acetyltransferase and sulphontransferase
(aromatic amines). Surprisingly, epoxide hydrolase, which is
involved in epoxide detoxification and which is polymor-
phically expressed, was not given much coverage, although
the importance of the N-acetylation phenotype to the car-
cinogenic effect of arylamines was included.
Section 3, which partially overlaps with Section 2, is about
gene regulation ofxenobiotic metabolising enzymes. In a field
moving as fast as this there are naturally some areas which
have progressed since the reviews were written and one can
find omissions such as y-glutamyl transpeptidase. However
other areas which are well reported are the regulation of
cytochrome P-450, the elegant studies on the nuclear
glucocorticoid receptor, regulation of DT-diaphorase, and
expression of glutathione transferases. The important effects
of xenobiotics on signal transduction and Ca2+ concentra-
tions, (although not particularly appropriate to the section
title), are also discussed.
Resistance processes to cancer drugs from the basis of
Section 4. Resistance to many drugs is associated with the
expression of a 170 kD glycoprotein (P-glycoprotein), whose
function is clearly reviewed. Exciting prospects exist for anti-
cancer agents which could block the transport activity of
P-glycoprotein. Other enzymes involved in resistance which
are discussed are glutathione transferases (GST), glyoxalase I
and UDP-glucuronosyl transferases. The first of these
enzymes appears under different roles in each of Sections 2, 3
and 4. Although it might have been a challenging task for a
contributor, an overall summary with a unifying hypothesis
on function, polymorphism etc. of GST might have been
interesting to include.
The next shorter section covers xenobiotics as a cause of
human cancer. Three papers cannot even scratch the surface
of this subject, and indeed only one class of compounds (the
hetrocyclic amines) are considered in detail. (It however
maybe appropriate to choose these as the sole example in this
volume, in view of the pioneering work carried out by the
Japanese on hetrocyclic amines in cooked food.) To make up
for the deficiency in covering other compounds there is a
penetrating and though-provoking review by Ames et al.
pointing out the importance of concentrating our attention
on natural chemicals, in addition to the synthetic chemicals
which have previously occupied many regulators' minds.
One real possibility for determining which xenobiotics are
involved in human cancer initiation rests in the novel discip-
lines of 'biomonitoring', reviewed in Section 6. These techni-
ques allow the detection of carcinogen adducts with DNA at
levels down to ca. 1 modified DNA base per cell. Screening
systems to monitor qualitatively and quantitatively exposures
to mixtures of carcinogens are being developed using
measurements of both DNA and protein (especially haemo-
globin) adducts. Four papers review the major techniques
employed (32P-postlabelling, immunoassays, gas chromato-
graphy/mass spectrometry) for DNA and protein adduct
measurements, and the relation of these data with mutations
and chromosomal changes is discussed. This is a most inter-
esting section of the book, and an appropriate one for its
conclusion. Again because of the pace ofprogress in this area
we know now of interesting novel findings, for example
relating to mutation of the p53 gene, which could not have
been included at the time of writing. This sadly is
unavoidable in a publication now of a meeting held 18
months ago.
The book is notable for its high quality of editing and
would certainly be a valuable addition to the bookshelves of
chemical or biological carcinogenicists. The range of topics
reviewed, although not comprehensive, is wide and the book
is a useful source of up to date knowledge on molecular
findings in chemical carcinogenesis.
P. Farmer